These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 29368970)

  • 21. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
    Peters AL; Buschur EO; Buse JB; Cohan P; Diner JC; Hirsch IB
    Diabetes Care; 2015 Sep; 38(9):1687-93. PubMed ID: 26078479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Canagliflozin-associated Diabetic Ketoacidosis with Lower-than-anticipated Glucose Levels.
    Vadi S; Agarwal M
    Indian J Crit Care Med; 2017 Nov; 21(11):793-795. PubMed ID: 29279644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor.
    Andrews TJ; Cox RD; Parker C; Kolb J
    J Emerg Med; 2017 Feb; 52(2):223-226. PubMed ID: 27717592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Outcome studies on SGLT-2 inhibitors].
    Seufert J; Laubner K
    Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Euglycemic Ketoacidosis With Sodium-Glucose Cotransporter-2 Inhibitor.
    Koch RA; Clark RF
    Am J Ther; 2018; 25(5):e590-e591. PubMed ID: 28452848
    [No Abstract]   [Full Text] [Related]  

  • 26. When Guidelines Fail: Euglycemic Diabetic Ketoacidosis After Bariatric Surgery in a Patient Taking a Sodium-Glucose Cotransporter-2 Inhibitor: A Case Report.
    Lane S; Paskar D; Hamed S; Goffi A
    A A Pract; 2018 Jul; 11(2):46-48. PubMed ID: 29634546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SGLT2 Inhibitors and Euglycemic Ketoacidosis.
    Masuta P; Johri G; Paul M
    Am J Ther; 2018; 25(4):e498-e500. PubMed ID: 28537992
    [No Abstract]   [Full Text] [Related]  

  • 28. Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.
    Peters AL; Henry RR; Thakkar P; Tong C; Alba M
    Diabetes Care; 2016 Apr; 39(4):532-8. PubMed ID: 26989182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ‘Euglycemic’ Ketoacidosis in a Patient With Type 2 Diabetes Being Treated With Canagliflozin.
    Danford C; Chan P; Magill SB
    WMJ; 2016 Aug; 115(4):206-9. PubMed ID: 29099159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Canagliflozin-Induced Diabetic Ketoacidosis: Case Report and Review of the Literature.
    Turner J; Begum T; Smalligan RD
    J Investig Med High Impact Case Rep; 2016; 4(3):2324709616663231. PubMed ID: 27635409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Euglycaemic diabetic ketoacidosis in bariatric surgery patients with type 2 diabetes taking canagliflozin.
    van Niekerk C; Wallace J; Takata M; Yu R
    BMJ Case Rep; 2018 Aug; 2018():. PubMed ID: 30131409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium-glucose cotransporter-2 inhibitors induced eu-glycemic diabetic ketoacidosis: The first report in a type 2 diabetic (T2D) Taiwanese and literature review of possible pathophysiology and contributing factors.
    Lin YH
    J Formos Med Assoc; 2018 Sep; 117(9):849-854. PubMed ID: 29477576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin.
    Bader N; Mirza L
    Pak J Med Sci; 2016; 32(3):786-8. PubMed ID: 27375734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in the perioperative setting.
    Peacock SC; Lovshin JA
    Can J Anaesth; 2018 Feb; 65(2):143-147. PubMed ID: 29159514
    [No Abstract]   [Full Text] [Related]  

  • 35. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.
    Lupsa BC; Inzucchi SE
    Diabetologia; 2018 Oct; 61(10):2118-2125. PubMed ID: 30132031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.
    Erondu N; Desai M; Ways K; Meininger G
    Diabetes Care; 2015 Sep; 38(9):1680-6. PubMed ID: 26203064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SGLT2 Inhibitors and Ketoacidosis: Cause for Concern?
    Abate N; Chandalia M
    Metab Syndr Relat Disord; 2016 Feb; 14(1):1-2. PubMed ID: 26554527
    [No Abstract]   [Full Text] [Related]  

  • 38. Canagliflozin-associated diabetic ketoacidosis: a case report.
    Chai PR; Bonney C; Blohm E; Boyer EW; Babu KM
    Toxicol Commun; 2017; 1(1):2-5. PubMed ID: 29978156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
    Oguma T; Kuriyama C; Nakayama K; Matsushita Y; Yoshida K; Kiuchi S; Ikenaga Y; Nakamaru Y; Hikida K; Saito A; Arakawa K; Oka K; Ueta K; Shiotani M
    J Pharmacol Sci; 2015 Apr; 127(4):456-61. PubMed ID: 25892328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Euglycemic diabetic ketoacidosis in type 2 diabetes with sodium glucose cotransporter 2 inhibitors.
    Wang AY; Hou SK; Li SJ; Kao WF
    Am J Emerg Med; 2017 Feb; 35(2):379.e5-379.e6. PubMed ID: 27614369
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.